JAN 02, 2018 10:18 AM PST

FDA Approves Genomic Profiling Tests to Improve Cancer Care

WRITTEN BY: Julia Travers

In December 2017, the Food and Drug Administration (FDA) approved a new genomic profiling test – the second in two months. This test, known as FoundationOne CDx (F1CDx) identifies alterations in a patient’s genes and can be used as a companion diagnostic screen for 15 therapies treating five cancers: non-small cell lung cancer, melanoma, breast cancer, colorectal cancer and ovarian cancer.

DNA illustration, credit: ghr.nlm.nih.gov

When used as a companion diagnostic, F1CDx determines if a certain therapy is viable for a patient based on whether their tumor displays a specific genetic alteration. It can identify alterations associated with cancer in 324 genes and two kinds of genomic signatures in solid tumors. F1CDx can detect specific mutations accurately 95 percent of the time.

"It's essentially individualized, precision medicine," Director and Chief Medical Officer for the Centers for Medicare & Medicaid Services (CMS) Kate Goodrich says of the newly approved test. When the FDA approval of F1CDx was announced in December, CMS also proposed national coverage for the test, along with other screenings offering next-generation gene-sequencing. This proposal is called a national coverage determination and requires a 30-day public comment period before being formalized.

Also, in November 2017, the FDA authorized a genomic profiling test called MSK-IMPACT. This test was developed solely for New York’s Memorial Sloan Kettering Cancer Center (MSKCC). It is able to scan tumor tissue samples for 468 cancer-associated alterations or mutations.

MSK-IMPACT has been shown to be able to identify actionable mutations (those that can be targeted with a known, approved drug or with one in a clinical trial) in 37 percent of patients with advanced solid cancers.

F1CDx and MSK-IMPACT are known as multigene tests and can retrieve a wealth of information from one tissue sample. Dr. Tracy Lively, chief of the Diagnostics Evaluation Branch of The National Cancer Institute (NCI)’s Division of Cancer Treatment and Diagnosis says this is very helpful because it can be hard to get ample tissue from a single biopsy for multiple unique tests.

“Both tests enable physicians to look at a broad range of genetic abnormalities in their patients’ tumors, some of which might be tied to particular approved drugs and some of which might be useful for other reasons,” she adds. One other potential use for the identification of tumor abnormalities she mentions is finding patients who can participate in clinical trials.

The NCI reports that the FDA also presented a streamlined regulatory approval process in 2017, which makes it cheaper and quicker for hospitals to get FDA authorization for in-house tumor-profiling tests. Lab tests that a single hospital develops and uses only in-house currently do not require FDA authorization to be used.

The FDA also approved a sequencing-based test called the Oncomine Dx Target Test in June 2017. This test was designed for patients who have lung cancer by the biotech company Thermo Fisher.

About the Author
  • Julia Travers is a writer, artist and teacher. She frequently covers science, tech and conservation.
You May Also Like
OCT 22, 2019
Cell & Molecular Biology
OCT 22, 2019
Insight Into a DNA Damage Sensor That Orchestrates Repair
Simple cell functions like division or metabolism can lead to DNA damage, which can also occur because of normal exposure to the sun or noxious agents....
OCT 22, 2019
Cancer
OCT 22, 2019
New method to stop metastasis in lymph nodes
Research reported recently in ACS Nano explains a new method of targeting metastases in lymph nodes as a means of preventing the spread of cancers. The app...
OCT 22, 2019
Cardiology
OCT 22, 2019
Exercise Produces Greater Benefits In Those With Cardiovascular Disease
The fact that exercise benefits the heart and can help a person live a longer healthier life is well established. Exercising regularly can improve quality...
OCT 22, 2019
Cancer
OCT 22, 2019
Early onset colorectal cancer on the rise
New research from the American Cancer Society and recently published in Gut shows that colorectal cancer in young adults is on the rise in high-income coun...
OCT 22, 2019
Cancer
OCT 22, 2019
Infant with leukemia saved by liver cancer drug
A young child just months old recently successfully received cancer treatment for an uncommon type of leukemia. The drug used in the treatment was not a ta...
OCT 22, 2019
Genetics & Genomics
OCT 22, 2019
Genetic Cause for Tumor Progression
Researchers from the University of Delaware (UDEL), Harvard Medical School (HMS) and University of California, Los Angeles (UCLA), have discovered a ribonu...
Loading Comments...